On this page
shingrix
Explore "shingrix" with insightful episodes like "3. Ophthalmic Shingles (Dr. Clara Chan)", "Shingles and the Shingles Vaccine", "35. Guideline for Vaccinations in Patients with Rheumatic and Musculoskeletal Diseases" and "MPR Weekly Dose 98 - FDA Committee Vote on Vaccines for Children; Booster Efficacy Results; Shingrix Recommendations; Novel Treatment for Macular Edema; Pepaxto Withdrawn" from podcasts like ""Blind Spot - The Eye Doctor's Podcast", "Driftless HealthCast", "ACR on Air" and "MPR Weekly Dose"" and more!
Episodes (4)
Shingles and the Shingles Vaccine
In this episode, Dr. Tookey and Dr. Wolbrink review Shingles (a painful rash caused by the same virus as chicken pox). They cover what symptoms you can experience as well as how to treat it. More importantly, they talk about the vaccine to prevent it and who should get it.
We're providing general guidance but everyone is different and you should always discuss with your health care professional management of any disease and therapy before trying anything you discover from a source on the internet (including this podcast). This podcast does not reflect the opinion of our employer.
35. Guideline for Vaccinations in Patients with Rheumatic and Musculoskeletal Diseases
In this week’s episode, we discuss the "ACR’s 2022 Guideline Summary for Vaccinations in Patients with Rheumatic and Musculoskeletal Diseases" with lead author Dr. Anne Bass, Attending Physician in the Division of Rheumatology at Hospital for Special Surgery and a Professor of Clinical Medicine at Weill Cornell Medicine. During our conversation we consider the importance of guidelines for vaccines, the impact certain drugs like rituximab and methotrexate have on vaccinations, cover some vaccine highlights within the guidelines, how these guidelines can aid in navigation with insurance companies and much, much more.
MPR Weekly Dose 98 - FDA Committee Vote on Vaccines for Children; Booster Efficacy Results; Shingrix Recommendations; Novel Treatment for Macular Edema; Pepaxto Withdrawn
The FDA votes on whether the Pfizer-BioNTech vaccine should be authorized in 5 to 11 year olds; The Moderna vaccine elicits strong antibody responses in pediatrics; Trial results shed light on booster dose efficacy; Shingrix is recommended for immunocompromised patients; A novel treatment is approved for macular edema associated with uveitis; And Pepaxto is withdrawn following new findings.